Role of arformoterol in the management of COPD

International Journal of COPD

Volumn 3, Issue 3, 2008, Pages 385-391

  King, Paul ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Arformoterol; COPD; Efficacy; Safety

Indexed keywords

ACETYLCYSTEINE; ARFORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FORMOTEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; SALMETEROL;

ANTIINFLAMMATORY ACTIVITY; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRY POWDER; FORCED EXPIRATORY VOLUME; HEART DEPOLARIZATION; HEART DISEASE; HEART RATE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; LUNG FUNCTION; METERED DOSE INHALER; NEBULIZER; NONHUMAN; PEAK EXPIRATORY FLOW; QT PROLONGATION; REVIEW; SIDE EFFECT; TACHYCARDIA; TREATMENT DURATION; TREMOR;

ADRENERGIC BETA-AGONISTS; ETHANOLAMINES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 54949144969     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Aalbers R, Ayres J, Backer V et al. 2002. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J, 19:936-43.
2. Abraha D, Cho SH, Agrawal DK et al. 2004. (S,S)-formoterol increases the production of IL-4 in mast cells and the airways of a murine asthma model. Int Arch Allergy Immunol, 133:380-8.
3. Ameredes BT, Hershman KL, Brown D et al. 2001. GM-CSF production by human airway smooth muscle cells treated with (R,R)- and (S,S)-enantiomers of formoterol. Am J Respir Crit Care Med, S513.
4. Anderson GP. 1993. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci, 52:2145-60.
5. Appleton S, Poole P, Smith B, et al.2006. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonaty disease. Cochrane Database Syst Rev, 3:CD001104.
6. Baluk P, McDonald DM. 1994. The beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am J Physiol, 266:461-8.
7. Baramki D, Koester J, Anderson AJ et al. 2002. Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol, 109:449-54.
8. Barnes PJ. 2000. Chronic obstructive pulmonary disease. N Engl J Med, 343:269-80.
9. Bartow RA, Brogden RN. 1998. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs, 55:303-22.
10. Baumgartner RA, Hanania NA, Calhoun WJ et al. 2007. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther, 29:261-78.
11. Baumgartner RA, Mazzetti A, Claus R. 2006. Crossover dose-ranging study of arformoterol in patients with COPD. Proc Am Thorac Soc, A847.
12. Berger WE, Nadel JA. 2008. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respir Med, 102:173-88.
13. Bonasia P, Cook C, Cheng Y et al. 2007. Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs. Curr Med Res Opin, 23:2477-83.
14. Brogden RN, Faulds D. Salmeterol xinafoate. 1991. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs, 42:895-912.
15. Calverley PM, Anderson JA, Celli B et al. 2007. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 356:775-89.
16. Campbell M, Eliraz A, Johansson G et al. 2005. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med, 99:1511-20.
17. Cheung D, Timmers MC, Zwinderman AH et al. 1992. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med, 327:1198-203.
18. Cockcroft DW, Davis BE, Swystun VA et al. 1999. Tolerance to the bronchoprotective effect of beta2-agonists: comparison of the enantiomers of salbutamol with racemic salbutamol and placebo. J Allergy Clin Immunol, 103:1049-53.
19. Dahl R, Greefhorst LA, Nowak D et al. 2001. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 164:778-84.
20. FitzGerald JM, Chapman KR, Della Cioppa G et al. 1999. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. J Allergy Clin Immunol, 103:427-35.
21. Giannini D, Carletti A, Dente FL et al. 1996. Tolerance to the protective effect of salmeterol on allergen challenge. Chest, 110:1452-7.
22. Greiff L, Wollmer P, Andersson M et al. 1998. Effects of formoterol on histamine induced plasma exudation in induced sputum from normal subjects. Thorax, 53:1010-13.
23. Handley DA, Senanayake CH, Dutczak W et al. 2002. Biological actions of formoterol isomers. Pulm Pharmacol Ther, 15:135-45.
24. Hanrahan JP. 2007. An open-label study of arformterol inhalatino solution and racemic formoterol dry-powder inhaler in subjects with COPD. Chest, A543.
25. Hanrahan JP, Calhoun WJ, Nelson JA et al. 2007b. An assessment of patient centred outcomes following treatment with nebulized arformoterol in patients with COPD. In Am J Resp Crit Care Med, A618.
26. Hanrahan JP, Hanania NA, Calhoun WJ et al. 2008. Effect of nebulized eformoterol on airway function in COPD: results from two randomized trials. COPD, 5:25-34.
27. Jeffery PK, Venge P, Gizycki MJ et al. 2002. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J, 20:1378-85.
28. Johnson M. 1995. Salmeterol. Med Res Rev, 15:225-57.
29. Ketchell RI, Jensen MW, Spina D et al. 2002. Dose-related effects of formoterol on airway responsiveness to adenosine 5′-monophosphate and histamine. Eur Respir J, 19:611-6.
30. Lipworth B, Tan S, Devlin M et al. 1998. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med, 104:431-8.
31. Lotvall J. 2001. Pharmacological similarities and differences between beta2-agonists. Respir Med, 95:7-11.
32. Lotvall J, Palmqvist M, Ankerst J et al. 2005. The effect of formoterol over 24 h in patients with asthma: the role of enantiomers. Pulm Pharmacol Ther, 18:109-13.
33. Mahler DA. 2002. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol, 110:298-303.
34. Mak JC, Grandordy B, Barnes PJ. 1994. High affinity [3H]formoterol binding sites in lung: characterization and autoradiographic mapping. Eur J Pharmacol, 269:35-41.
35. Maneechotesuwan K, Essilfie-Quaye S, Meah S et al. 2005. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest, 128:1936-42.
36. Matera MG, Cazzola M. 2007. Ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs, 67:503-15.
37. Mirza ZN, Kato M, Kimura H et al. 2002. Fenoterol inhibits superoxide anion generation by human polymorphonuclear leukocytes via beta-adrenoceptor-dependent and -independent mechanisms. Ann Allergy Asthma Immunol, 88:494-500.
38. Nelson JA, Strauss L, Skowronski M et al. 1998. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med, 339:141-6.
39. Nielson CP. 1987. Beta-adrenergic modulation of the polymorphonuclear leukocyte respiratory burst is dependent upon the mechanism of cell activation. J Immunol, 139:2392-7.
40. Nightingale JA, Rogers DF, Barnes PJ. 1999. Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. Am J Respir Crit Care Med, 159:1786-90.
41. O'Byrne PM, Bisgaard H, Godard PP et al. 2005. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med, 171:129-36.
42. O'Donohue JF, Hanania NA, Sciarappa K et al. 2007. Long-term safety of 50-ug once-daily nebulized arformoterol in COPD: a 12-month clinical trial. Am J Resp Crit Care Med, A127.
43. O'Donohue WJ, Jr. 1996. Guidelines for the use of nebulizers in the home and at domiciliary sites. Report of a consensus conference. National Association for Medical Direction of Respiratory Care (NAMDRC) Consensus Group. Chest, 109:814-20.
44. Rabe KF. 2001. Formoterol in clinical practice-safety issues. Respir Med, 95:21-5.
45. Rabe KF, Atienza T, Magyar P et al. 2006. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet, 368:744-53.
46. Rabe KF, Hurd S, Anzueto A et al. 2007. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 176:532-55.
47. Ramer-Quinn DS, Baker RA, Sanders VM. 1997. Activated T helper 1 and T helper 2 cells differentially express the beta-2-adrenergic receptor: a mechanism for selective modulation of T helper 1 cell cytokine production. J Immunol, 159:4857-67.
48. Roux FJ, Grandordy B, Douglas JS. 1996. Functional and binding characteristics of long-acting beta 2-agonists in lung and heart. Am J Respir Crit Care Med, 153:1489-95.
49. Salpeter SR, Buckley NS, Salpeter EE. 2006. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med, 21:1011-19.
50. Schmidt D, Kallstrom BL, Waldeck B et al. 2000. The effect of the enantiomers of formoterol on inherent and induced tone in guinea-pig trachea and human bronchus. Naunyn Schmiedebergs Arch Pharmacol, 361:405-9.
51. Simons FE, Gerstner TV, Cheang MS. 1997. Tolerance to the broncho-protective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics, 99:655-9.
52. Spitzer WO, Suissa S, Ernst P et al. 1992. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med, 326:501-6.
53. Steinke JW, Baramki D, Borish L. 2006. Opposing actions of (R,R)-isomers and (S,S)-isomers of formoterol on T-cell function. J Allergy Clin Immunol, 118:963-5.
54. Tokuyama K, Lotvall JO, Lofdahl CG et al. 1991. Inhaled formoterol inhibits histamine-induced airflow obstruction and airway microvascular leakage. Eur J Pharmacol, 193:35-9.
55. Totterman KJ, Huhti L, Sutinen E et al. 1998. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. Eur Respir J, 12:573-9.
56. Trofast J, Osterberg K, Kallstrom BL et al. 1991. Steric aspects of agonism and antagonism at beta-adrenoceptors: synthesis of and pharmacological experiments with the enantiomers of formoterol and their diastereomers. Chirality, 3:443-50.
57. Vaickus L, Claus R. 2000. (R,R)-formoterol: rapid onset and 24 h duration of response after a single dose. Am J Respir Crit Care Med, 161:191.
58. Waldeck B. 1993. Biological significance of the enantiomeric purity of drugs. Chirality, 5:350-5.
59. Yates DH, Sussman HS, Shaw MJ et al. 1995. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med, 152:1170-4.